{"id":"64cu-dotatate","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure (expected from PET imaging)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Transient hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL4297339","moleculeType":"Protein","molecularWeight":"1497.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"64Cu-DOTATATE consists of the radioisotope copper-64 conjugated to DOTATATE, a somatostatin analog that selectively targets somatostatin receptor subtype 2 (SSTR2) expressed on neuroendocrine tumors. The copper-64 emits positrons enabling PET imaging to localize and visualize tumors. This allows clinicians to detect, stage, and monitor neuroendocrine neoplasms with high specificity.","oneSentence":"64Cu-DOTATATE is a radioactive diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing detection via positron emission tomography (PET).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:01.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of somatostatin receptor-positive neuroendocrine tumors"},{"name":"Detection and staging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"}]},"trialDetails":[{"nctId":"NCT06122610","phase":"PHASE1","title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-03-07","conditions":"Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":"Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":15},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":"Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":11},{"nctId":"NCT06016855","phase":"PHASE4","title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-05-31","conditions":"Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm","enrollment":6},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT05432427","phase":"NA","title":"64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis.","status":"COMPLETED","sponsor":"Emil Loldrup Fosbol","startDate":"2022-04-28","conditions":"Endocarditis, Endocarditis;Chronic, Endocarditis Acute","enrollment":69},{"nctId":"NCT06392815","phase":"NA","title":"64Cu-DOTATATE-PET for Lyme Neuroborreliosis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-05-20","conditions":"Borrelia Burgdorferi Neuroborreliosis","enrollment":50},{"nctId":"NCT05709171","phase":"PHASE2","title":"Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2023-01-17","conditions":"GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma","enrollment":200},{"nctId":"NCT06131112","phase":"","title":"Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-11-01","conditions":"Cardiac Sarcoidosis","enrollment":76},{"nctId":"NCT04949282","phase":"","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","status":"RECRUITING","sponsor":"Sociedad Española de Medicina Nuclear e Imagen Molecular","startDate":"2021-05-10","conditions":"Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms","enrollment":5000},{"nctId":"NCT03673943","phase":"PHASE3","title":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","status":"COMPLETED","sponsor":"Radiomedix, Inc.","startDate":"2018-08-23","conditions":"Neuroendocrine Tumors","enrollment":63},{"nctId":"NCT02812849","phase":"","title":"Somatostatin Receptor Imaging in Cardiac Sarcoidosis","status":"WITHDRAWN","sponsor":"Rigshospitalet, Denmark","startDate":"2016-06","conditions":"Cardiac Sarcoidosis","enrollment":""},{"nctId":"NCT04334837","phase":"","title":"Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)","status":"APPROVED_FOR_MARKETING","sponsor":"Curium US LLC","startDate":"","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02125474","phase":"NA","title":"Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia, Columbia","startDate":"2013-11","conditions":"Neuroendocrine Tumors","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NETMEDIX","Detectnet","Copper (64Cu) oxodotreotide"],"phase":"phase_3","status":"active","brandName":"64Cu-DOTATATE","genericName":"64Cu-DOTATATE","companyName":"Radiomedix, Inc.","companyId":"radiomedix-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"64Cu-DOTATATE is a radioactive diagnostic imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing detection via positron emission tomography (PET). Used for Imaging of somatostatin receptor-positive neuroendocrine tumors, Detection and staging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}